Skip to main content

Health condition · Clinically reviewed

Oesophageal cancer, from first dysphagia to modern targeted therapy.

Around 9,000 people are diagnosed each year in the UK. A specialist upper GI team, careful staging and modern combinations of surgery, chemotherapy and immunotherapy transform what is possible.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE NG83, NG12, BSG and AUGIS standards you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including FLOT chemotherapy, immunotherapy and CLDN18.2 targeted therapy.

Key facts

Oesophageal cancer at a glance.

The essentials, in plain English - what it is, who gets it, the tests that make the diagnosis, and how it’s treated in the UK today.

  • What it is

    A cancer arising from the lining of the oesophagus - the muscular tube connecting the throat to the stomach - with around 9,000 UK cases each year.

  • Two main types

    Adenocarcinoma (rising in the UK, distal oesophagus and gastro-oesophageal junction) and squamous cell carcinoma (proximal and mid-oesophagus).

  • Cardinal symptom

    Progressive dysphagia - difficulty swallowing solids first, then liquids - is the classic and often late presenting feature.

  • Barrett oesophagus

    Metaplastic change from long-standing acid reflux is the main precursor to adenocarcinoma - surveillance and RFA reduce risk.

  • Molecular tests

    HER2 (around 20% of adenocarcinomas), MSI/dMMR, PD-L1 and CLDN18.2 guide targeted therapy and immunotherapy.

  • Modern treatment

    Endoscopic resection for early disease, neoadjuvant chemoradiotherapy (CROSS) or FLOT chemotherapy, plus surgery, immunotherapy and palliative care.

Why this guide matters

Two cancers, one tube, very different biology.

Adenocarcinoma and squamous cell carcinoma sit in the same organ but behave differently. Getting the type right, staging carefully and treating in a specialist centre is what changes outcomes.

  • Adenocarcinoma is rising in the UK

    Driven by reflux, Barrett oesophagus and obesity, adenocarcinoma of the distal oesophagus and gastro-oesophageal junction is now the most common form here.

  • Squamous cell carcinoma still matters

    Smoking, alcohol, hot beverages, achalasia, HPV and dietary nitrosamines drive proximal and mid-oesophageal squamous cell cancers - which respond very well to chemoradiotherapy.

  • Molecular testing changes the plan

    HER2, MSI, PD-L1 and CLDN18.2 status determine whether trastuzumab, pembrolizumab, nivolumab or zolbetuximab are added to the treatment plan.

How the diagnosis is made

From new dysphagia to a specialist plan.

The steps a UK GP, gastroenterologist and upper GI oncology MDT will normally follow - so you know what to expect and why.

  1. 01

    Referral

    Two-week-wait referral

    Under NICE NG12, any new dysphagia at any age, or weight loss with upper GI symptoms over 55, triggers an urgent suspected cancer referral.

  2. 02

    Referral

    Upper GI endoscopy (OGD)

    A gastroscopy with biopsies is the definitive first test - it confirms the tumour, its position and histological type.

  3. 03

    Referral

    CT chest, abdomen and pelvis

    Staging CT looks for distant spread, nodal disease and the local extent of tumour before treatment planning.

  4. 04

    Staging

    PET-CT and endoscopic ultrasound

    PET-CT refines distant staging; EUS is the most accurate way to assess tumour depth (T) and local nodes (N) - specialist commissioned in the UK.

  5. 05

    Staging

    Selective MRI and laparoscopy

    MRI helps in specific cases; staging laparoscopy is used for junctional tumours to exclude peritoneal disease before surgery.

  6. 06

    MDT

    Molecular and biomarker testing

    HER2, MSI/dMMR, PD-L1 and CLDN18.2 testing shape decisions about trastuzumab, immunotherapy and zolbetuximab.

  7. 07

    MDT

    Specialist upper GI MDT

    Every case is discussed by a specialist-commissioned upper GI oncology MDT alongside a nutritional assessment before a plan is finalised.

Typical timeline: from 2WW referral to specialist MDT plan in a matter of weeks.

Symptoms

What oesophageal cancer feels like.

A pattern of progressive swallowing difficulty, weight loss and reflux change, occasionally with anaemia, bleeding or hoarseness. And the signs that mean urgent review.

  • Progressive dysphagia

    Difficulty swallowing solids first, then softer foods and liquids - the cardinal symptom and often the reason people are referred.

  • Weight loss and anorexia

    Unintentional weight loss, reduced appetite and early satiety are common and warrant urgent assessment.

  • Odynophagia and chest pain

    Painful swallowing or retrosternal discomfort, particularly with hot or hard foods, can point to an oesophageal lesion.

  • Regurgitation and reflux change

    New or worsening reflux, regurgitation of undigested food or a sensation of food sticking should prompt investigation.

  • Iron deficiency anaemia

    Occult bleeding can cause tiredness and iron deficiency - see our guide on gastrointestinal bleeding for context.

  • Haematemesis and melaena

    Vomiting blood or passing black, tarry stools is a red flag needing same-day assessment.

  • Hoarseness and cough

    A persistent hoarse voice (recurrent laryngeal nerve involvement) or chronic cough can signal local invasion or a late fistula.

  • Red flag - Virchow node or Horner

    A left supraclavicular lymph node, Horner syndrome or migratory thrombophlebitis (Trousseau) suggest advanced disease and need urgent review.

Reflux is a common driver of adenocarcinoma - see our guides on gastro-oesophageal reflux disease and gastrointestinal bleeding for context.

Treatment

How oesophageal cancer is treated in the UK.

Endoscopic therapy for early disease, CROSS chemoradiotherapy or FLOT chemotherapy plus oesophagectomy for localised cancer, and targeted or immunotherapy for advanced disease - all delivered through a specialist upper GI MDT.

  • Lifestyle and reflux control

    Smoking cessation, alcohol reduction, weight management and effective treatment of GORD reduce recurrence and support every other treatment.

  • Endoscopic resection

    For T1a intramucosal cancers, EMR and ESD offer curative removal without surgery - specialist commissioned in UK upper GI centres.

  • RFA for Barrett dysplasia

    Radiofrequency ablation eradicates dysplastic Barrett oesophagus and lowers progression to adenocarcinoma - see our RFA Barrett guide.

  • Neoadjuvant chemoradiotherapy

    The CROSS regimen (carboplatin, paclitaxel and 41.4 Gy radiotherapy) before oesophagectomy is a UK standard for localised disease.

  • Oesophagectomy

    Ivor-Lewis, McKeown or transhiatal resection, increasingly performed as minimally invasive or robotic surgery in specialist upper GI centres.

  • FLOT chemotherapy

    Peri-operative fluorouracil, leucovorin, oxaliplatin and docetaxel is the preferred adjuvant approach for junctional adenocarcinoma per FLOT-4.

  • HER2 targeted therapy

    For HER2-positive advanced adenocarcinoma, trastuzumab with chemotherapy (ToGA regimen) improves outcomes - see our HER2 clinic page.

  • Immunotherapy

    Pembrolizumab and nivolumab are NICE-approved options for advanced and adjuvant settings, supported by CheckMate-577 and KEYNOTE-590.

  • Zolbetuximab (anti-CLDN18.2)

    MHRA-approved in 2024 for CLDN18.2-positive gastric and gastro-oesophageal junction adenocarcinoma, with chemotherapy - specialist commissioned.

  • Definitive chemoradiotherapy

    A non-surgical curative option, particularly effective for squamous cell carcinoma and for patients unfit for oesophagectomy.

  • Palliative dysphagia relief

    Self-expanding oesophageal stents, brachytherapy, external beam radiotherapy and laser therapy restore swallowing and comfort.

  • Nutrition and PEG support

    Dietitian-led nutritional planning, oral supplements and, where needed, PEG feeding preserve weight and treatment tolerance.

Related procedures include gastroscopy, endoscopic ultrasound, RFA for Barrett oesophagus, HER2 targeted therapy, immunotherapy and palliative oesophageal stenting.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, specialist society standards and regulator statements, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP, gastroenterologist or upper GI oncology team knows your case and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Oesophago-gastric cancer: assessment and management in adults (NG83).

  • NICE. Suspected cancer: recognition and referral (NG12).

  • British Society of Gastroenterology (BSG). Barrett oesophagus and oesophageal cancer guidelines.

  • Association of Upper Gastrointestinal Surgery of Great Britain and Ireland (AUGIS). Service and quality standards.

  • MHRA. Zolbetuximab approval for CLDN18.2-positive gastric and GOJ adenocarcinoma (2024).

  • Cancer Research UK and Macmillan Cancer Support. Patient information on oesophageal cancer.

Red flags

When symptoms need urgent attention.

These features trigger a NICE two-week-wait referral or same-day assessment. If any apply, contact your GP now, or seek emergency care for bleeding, chest pain or breathlessness.

  • New dysphagia at any age

    Difficulty swallowing solids or liquids is a NICE two-week-wait indication regardless of age and needs urgent endoscopy.

  • Weight loss with upper GI symptoms

    Over 55 with weight loss and reflux, dyspepsia or upper abdominal pain warrants a 2WW suspected cancer referral.

  • Upper abdominal mass

    A palpable epigastric mass on examination is a red flag and needs same-week imaging and specialist review.

  • GI bleeding

    Haematemesis, coffee-ground vomiting or melaena needs urgent assessment - see our gastrointestinal bleeding guide.

  • Aspiration pneumonia

    Recurrent chest infections in someone with dysphagia may indicate an oesophago-tracheal fistula and need urgent imaging.

  • Virchow node

    A left supraclavicular node (Troisier sign) suggests distant nodal spread and demands urgent oncology input.

  • Trousseau syndrome

    Migratory superficial thrombophlebitis can precede a diagnosis of upper GI malignancy and needs work-up.

  • Persistent hoarseness

    New, persistent voice change with dysphagia raises concern for recurrent laryngeal nerve involvement.

  • Barrett oesophagus with dysplasia

    High-grade dysplasia on Barrett surveillance needs prompt discussion with a specialist upper GI centre for endoscopic therapy.

Living with it

A serious diagnosis, with real support around you.

Nutrition, reflux control, staying connected to the specialist team and using national support services make the biggest day-to-day difference through diagnosis and beyond.

A quiet reminder

You do not have to do this alone.

Clinical nurse specialists, dietitians, palliative teams and national charities exist for exactly this reason - use them from day one, not only when things are hard.

  1. 01 Nutrition

    Eat little and often

    Small, frequent, softer meals with high-energy supplements protect weight and treatment tolerance - dietitian input matters early.

  2. 02 Reflux

    Take reflux seriously

    Ongoing acid control, weight management and posture help protect the oesophagus - especially after any Barrett or reflux diagnosis.

  3. 03 Team

    Stay with your MDT

    Specialist upper GI centres deliver the best outcomes - keep every appointment and use your clinical nurse specialist as a first point of contact.

  4. 04 Support

    Use national support services

    Cancer Research UK, Macmillan and the Oesophageal Patients Association provide practical, emotional and financial help throughout treatment.

Frequently asked

Everything we get asked about oesophageal cancer.

Quick answers on risk factors, staging, surgery, chemotherapy, immunotherapy and palliative care.

  • What is oesophageal cancer?

    Oesophageal cancer is a malignant tumour of the lining of the oesophagus. In the UK, adenocarcinoma - usually in the lower oesophagus or gastro-oesophageal junction - is now more common than squamous cell carcinoma, which typically arises in the upper and mid-oesophagus.

  • What are the main risk factors?

    For adenocarcinoma: long-standing gastro-oesophageal reflux disease, Barrett oesophagus, obesity, smoking, alcohol, hiatus hernia, older age and male sex. For squamous cell carcinoma: smoking, alcohol, achalasia, HPV, very hot beverages, dietary nitrosamines, Plummer-Vinson syndrome and rare inherited conditions like tylosis.

  • Why is dysphagia the classic symptom?

    The oesophagus is a muscular tube, and tumours narrow the lumen as they grow. Solids catch first, then softer foods, then liquids. Because the oesophagus stretches, symptoms often appear only when the tumour is already sizeable, which is why any new swallowing difficulty needs an urgent endoscopy.

  • How is it staged?

    After endoscopy and biopsies, staging includes a CT of the chest, abdomen and pelvis, a PET-CT for distant disease, and endoscopic ultrasound (EUS) for accurate T and N staging. Selective MRI and staging laparoscopy are added for junctional tumours. Every case is discussed at a specialist upper GI MDT.

  • What treatment can I expect in the UK?

    Early T1a cancers can be cured by endoscopic resection. Localised disease is treated with neoadjuvant chemoradiotherapy (CROSS) or peri-operative FLOT chemotherapy followed by oesophagectomy in a specialist centre. Squamous cell tumours may be cured with definitive chemoradiotherapy. Advanced disease is treated with chemotherapy, immunotherapy, HER2-targeted therapy or zolbetuximab depending on molecular profile.

  • What are the palliative options if cure isn’t possible?

    Palliative care focuses on swallowing, nutrition and quality of life. Self-expanding oesophageal stents restore swallowing quickly; brachytherapy and external beam radiotherapy can shrink the tumour; laser therapy, PEG feeding and dietitian support help maintain weight. Specialist palliative care teams work alongside oncology throughout.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.